Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Researchers from the Max Planck Institute of Biochemistry have discovered the mechanism behind an important step in the life ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

President Donald Trump has put millions of lives at risk by shutting down most of America’s humanitarian and development work ...

This funding request comes in response to a recent US executive order that has impacted global health funding, including support for HIV programmes in Kenya.

North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...

LEN is a first-in-class, long-acting HIV-1 capsid inhibitor that disrupts multiple stages of the viral replication cycle. By binding to the capsid protein, it blocks the nuclear import of HIV-1 ...

Researchers reveal new insights into the how the matrix layer of HIV-1 becomes matureResearchers from the Max Planck Institute of Biochemistry have ...

In some populations, HIV infection is actually increasing. And we still don't have a vaccine. That's why scientists studying AIDS continue to search for weak spots in the virus's infection cycle.

This step is essential in the HIV replication cycle and is also responsible for establishing chronic disease. Rilpivirine is an NNRTI that works by interfering with an enzyme called reverse ...